CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

NCT00291668 ·Status: COMPLETED ·Phase: PHASE2

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

NCT00308581 ·Status: COMPLETED ·Phase: PHASE3

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

NCT00307931 ·Status: TERMINATED ·Phase: PHASE3

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

NCT00354367 ·Status: WITHDRAWN ·Phase: PHASE3

Study of Cimzia for the Treatment of Ulcerative Colitis

NCT01090154 ·Status: COMPLETED ·Phase: PHASE2

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

NCT01053559 ·Status: COMPLETED ·Phase: NA

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

NCT00358683 ·Status: WITHDRAWN ·Phase: PHASE3

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410 ·Status: COMPLETED ·Phase: PHASE2

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

NCT00152490 ·Status: COMPLETED ·Phase: PHASE3

Mucosal Healing Study in Crohn's Disease (CD)

NCT00297648 ·Status: COMPLETED ·Phase: PHASE3

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788 ·Status: COMPLETED ·Phase: PHASE3

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752 ·Status: TERMINATED ·Phase: PHASE3

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

NCT01582568 ·Status: TERMINATED

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

NCT01577264 ·Status: TERMINATED

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

NCT00152425 ·Status: COMPLETED ·Phase: PHASE3

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

NCT00160524 ·Status: COMPLETED ·Phase: PHASE3

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

NCT01393626 ·Status: COMPLETED ·Phase: PHASE2

An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

NCT03362736 ·Status: NO_LONGER_AVAILABLE

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

NCT00615199 ·Status: COMPLETED ·Phase: PHASE2

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

NCT01817972 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

NCT04643483 ·Status: WITHDRAWN ·Phase: PHASE3

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706 ·Status: COMPLETED ·Phase: PHASE3

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

NCT00844285 ·Status: COMPLETED

Cimzia Versus Mesalamine for Crohn's Recurrence

NCT01696942 ·Status: TERMINATED ·Phase: PHASE4

Treg Immunotherapy in Crohn's Disease

NCT03185000 ·Status: UNKNOWN ·Phase: PHASE1